- Business Wire•2 hours agoAlnylam Presents Updated Results from Phase 1/2 Study of ALN-CC5 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today presented new results from Part C of its Phase 1/2 clinical trial with ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component 5 for the treatment of complement-mediated diseases, in a poster presentation at the 58th Annual Meeting of the American Society of Hematology , held ...
- Zacks•6 hours ago
Alnylam (ALNY) announced new positive data from an ongoing phase II OLE study on fitusiran for the treatment of patients with hemophilia A or B, without inhibitors.
ALNY : Summary for Alnylam Pharmaceuticals, Inc. - Yahoo Finance
Alnylam Pharmaceuticals, Inc. (ALNY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||41.31 x 300|
|Ask||41.32 x 200|
|Day's Range||39.20 - 42.63|
|52 Week Range||31.38 - 105.84|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-9.11|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|